ELDN Insider Trading - Eledon Pharmaceuticals, Inc.

발행주식수	77,187,823 shares
내부자 지분	27,921,493 shares
내부자 주주	36.17 %
전체 내부자	49

내부자 센티멘트 점수

내부자 센티멘트 점수를 통해서 내부자들이 법인 지분을 매입하는 기업들에 대해서 알아볼 수 있습니다.

이는 내부자의 누적도가 가장 높은 기업을 식별하는 정교하고 복합적인 지수를 분석하는 계량 모델의 결과 값입니다. 스코어링 모델은 이전 90일 동안 매수한 "내부자의 순 숫자", "매수한 주식의 총합", "내부자가 소유한 주식의 총합"의 조합을 사용합니다. 점수는 0에서 100 사이이며, 점수가 높을수록 피어(Peer: 동종업계 경쟁기업)에 대한 누적도가 높다는 것을 나타내며, 평균은 50입니다.

업데이트 주기: 일별

내부자의 누적도가 가장 높은 기업 목록을 확인할 수 있는 내부자들의 최다 선택(Insiders Top Picks)을 참고하십시오.

가장 높은 순위의 주식을 확인하세요

내부 경영진 센티멘트 점수

내부 경영진 센티멘트 점수를 통해서 내부 경영진들이 법인 지분을 매입하는 기업들에 대해서 알아볼 수 있습니다.

내부 거래의 정의에 따라 내부 경영진(기업 임원)도 내부자이지만, 다른 내부자(10% 주주 및 이사회 구성원)들과는 달리 내부 경영진은 매일 회사에서 근무하며, 거래 시에 자신의 자금을 사용합니다. (많은 경우에 10% 주주 및 이사회 구성원은 다른 사람의 자금을 관리하는 자금 관리자입니다.) 따라서 내부 경영진(기업 임원: Officer)의 내부 거래는 훨씬 더 중요하며 올바른 분석이 필요합니다.

내부자 센티멘트 점수와 마찬가지로 임원 감정 점수는 가장 높은 수준의 임원 축적을 가진 기업을 식별하는 정교하고 복합적인 지수 퀀트(Multi-factor quantitative) 모델의 결과입니다.

업데이트 주기: 일별

내부자의 누적도가 가장 높은 기업 목록을 확인할 수 있는 내부자들의 최다 선택(Insiders Top Picks)을 참고하십시오.

가장 높은 순위의 주식을 확인하세요

주요 내부자 지표

이 수치는 해당 기업이 다양한 내부자 지표에 따라 어떻게 순위를 매겨지는 지를 설명합니다. 백분위 순위는 이 기업이 미국 시장의 다른 기업들과 어떻게 비교되는지 보여줍니다. 순위가 높을수록 더 나은 상황에 있다는 것을 의미합니다.

예를 들어, 일반적으로 내부자의 매입은 긍정적인 지표라고 간주되어지기 때문에, 내부자의 매입(내부자의 매각, 역시도)가 적은 기업보다 내부자의 매입이 많은 기업은 순위가 높을 것입니다.

내부자의 순 매입(순위)

0 ( )

2530 out of 10916

내부자의 순 매입(Net Number of Insiders Buying)는 내부자 매수의 총 수에서 지난 90일 동안의 내부자 매도의 총 수를 뺀 값입니다. 여기에 백분위 순위가 표시됩니다(범위: 0~100%).

내부자가 매입한 플로트 비율 (순위)

0.000% ( )

2555 out of 10752

"내부자가 매입한 플로트 비율(Percent of Float Bought by Insiders)"은 내부자가 매입한 주식의 총 수에서 내부자가 매도한 주식의 총 수를 뺀 값을 전체 플로트로 나눈 값에 100을 곱한 값입니다. * ((내부자가 매입한 주식의 총 수 - 내부자가 매도한 주식의 총 수) ÷ 전체 플로트) x 100

내부자 트레이딩 차트

Eledon Pharmaceuticals, Inc. 내부자의 매매 거래는 아래 차트에 나와 있습니다. 내부자들은 기업의 임원(내부 경영진), 이사 또는 주요 투자자입니다. 일반적으로 내부자가 중요한 비공개 정보를 기반으로 자신이 속한 기업을 거래하는 것은 불법으로 간주됩니다. 이것은 내부자가 자신의 기업 내에서 행하는 모든 거래가 불법이라는 것을 뜻은 아닙니다. 그러나 그들은 자신들의 모든 거래를 양식 4를 통해 SEC에 보고해야만 합니다.

내부자의 명단 및 이익 지표

아래 표는 공개된 내부자의 목록이며, SEC에 공개된 제출 문서에서 자동으로 생성됩니다. "이름", "가장 최근의 직급", "이사, 임원 또는 10% 주주"에 대한 지정 외에도 최근에 공개된 보유 주식에 대한 정보를 보여줍니다. 또한 가능한 경우 내부자의 과거 거래 실적도 확인 가능합니다. 과거 거래 실적은 내부자가 실제 "공개 시장"(Open market) 매입 거래를 수행한 실적을 가중 평균한 값입니다. 이 계산 방법에 대한 자세한 내용은 유튜브 웨비나 를 참조하시면 됩니다.

See our leaderboard of most profitable insider traders.

내부자	소유 지분	주식 분할
Apple Tree Partners Ii Lp Director, 10% Owner - [D] [10%]	4,218,641	4,218,641
Apple Tree Partners II - Annex, L.P. Director, 10% Owner - [D] [10%]	3,568,438	3,568,438
Apple Tree Partners IV, L.P. Director, 10% Owner - [D] [10%]	250,000	250,000
Timothy J Barberich Director - [D]	121,077	121,077
Biotechnology Value Fund Ii Lp -	113,152	220,460
Biotechnology Value Fund L P -	113,152	220,460
Bvf Gp Holdings Llc 10% Owner - [10%]	113,152	220,460
Bvf I Gp Llc -	113,152	220,460
Bvf Ii Gp Llc -	113,152	220,460
Bvf Inc/il 10% Owner - [10%]	113,152	220,460
Bvf Partners L P/il 10% Owner - [10%]	220,460	220,460
BVF Partners OS Ltd. -	113,152	220,460
Biotechnology Value Trading Fund OS LP -	113,152	220,460
Buckley Stephen Jr. Director - [D]	11,000	11,000
Erez Chimovits Director - [D]	3,183,314	3,183,314
Cheryl Cohen Director - [D]	0	0

내부자	소유 지분	주식 분할
Flesher Gregory J. Chief Executive Officer, Director - [D] [O]	156,918	156,918
Karen Jean Ferrante	62,000
David-Alexandre C Gros Chief Executive Officer, Director - [D] [O]	9,000	9,000
Seth Loring Harrison Director, 10% Owner - [D] [10%]	7,912,079	7,912,079
Jan Hillson Director - [D]	3,430	3,430
Lee Kalowski Chief Financial Officer - [O]	40,953	40,953
Keith Katkin Director - [D]	8,575	8,575
Kessler David A.	12,000
Allan Kirk Director - [D]	3,430	3,430
Jon Kuwahara See Remarks - [O]	5,974	5,974
Mark N Lampert 10% Owner - [10%]	113,152	220,460
Lifesci Index Partners Llc 10% Owner - [10%]	1,065,867	1,065,867
Gary A Lyons Director - [D]	0	0
June Lee Director - [D]	3,430	3,430
Paul Sean Little CHIEF FINANCIAL OFFICER - [O]	10,000	10,000
Logos Global Management LP 10% Owner - [10%]	224,071	224,071

내부자	소유 지분	주식 분할
McBride John S. Director - [D]	3,430	3,430
Jodie Pope Morrison President and CEO, Director - [D] [O]	57,566	57,566
Ag Novartis 10% Owner - [10%]	4,493,458	4,493,458
Bioventures Ltd Novartis 10% Owner - [10%]	4,493,458	4,493,458
Christine Ocampo See Remarks - [O]	23,160	23,160
Walter C Ogier	20,000
OrbiMed Israel BioFund GP Limited Partnership Director, 10% Owner - [D] [10%]	73,650	73,650
OrbiMed Israel GP Ltd. 10% Owner - [10%]	73,650	73,650
Steven Perrin President, Director - [D] [O]	1,000	1,000
Gerald E Quirk	62,000
Robinson James A. Jr. Director - [D]	3,430	3,430
Muneer A Satter 10% Owner - [10%]	1,771,688	1,771,688
Smith Bryan E.	120,000
Turkel Catherine C. President - [O]	88,662	88,662
Martin D Williams 10% Owner - [10%]	337,700	337,700
Paul Yook 10% Owner - [10%]	1,065,867	1,065,867
Yanchik Joseph A., III Director - [D]	51,092	51,092

Report errors via our new Insider Auditing Tool

내부자의 매입 내역 추적: 단기 이익 분석

이 섹션에서는 ELDN / Eledon Pharmaceuticals, Inc.에서 계획되지 않은 "공개 시장"(Open market)의 내부자가 매입한 모든 상품의 수익성을 분석합니다. 이 분석을 통해서 내부자가 비정상적인 수익을 지속적으로 창출하는지 파악하는 데 도움이 되며, 이러한 분석은 수행해볼 가치가 있습니다. 이 분석은 개별 거래 후 1년 동안 수행한 것이며, 결과는 이론 값입니다. .

아래 표는 사전 거래 계획(Automated trading plan)에 포함되지 않은 가장 최근의 "공개 시장"(Open market)에서의 매입을 보여줍니다.

거래일	내부자	보고된 지분	보고된 가격	조정된 지분	조정된 가격	가격 기준	최고까지 일수	최고에서 가격
2024-05-09	BVF PARTNERS L P/IL	1,031,385		1,031,385			176	5.3000
2024-05-09	BVF PARTNERS L P/IL	821,121		821,121
2024-05-09	BVF PARTNERS L P/IL	75,431		75,431
2023-05-05	BVF PARTNERS L P/IL	1,055,445		1,055,445
2023-05-05	BVF PARTNERS L P/IL	837,146		837,146
2023-05-05	BVF PARTNERS L P/IL	86,341		86,341
2022-11-23	Perrin Steven	1,000	2.5969	1,000	2.5969	2,597
2021-12-20	Gros David-Alexandre C	2,000	4.4800	2,000	4.4800	8,960
2021-08-17	Gros David-Alexandre C	4,000	6.2100	4,000	6.2100	24,840

조정된 가격은 분할 조정 가격입니다. 조정된 지분은 분할 조정 지분입니다.

ELDN / Eledon Pharmaceuticals, Inc. Insider Trades

내부자 매매의 실적: 단기 손실 분석

이 섹선에서는 ELDN / Eledon Pharmaceuticals, Inc.에서 이루어진 "공개 시장(Open market)"에서의 모든 계획되지 않은 내부자 매매의 단기 손실 회피(Short-term loss avoidance)를 분석합니다. 일관된 손실 회피 패턴을 통해서 향후 매매 거래가 가격 하락을 초래할 수도 있음을 예상할 수 있습니다. 이 분석은 각 각 매매 거래 후 1년 동안의 자료이며, 결과는 이론 값입니다. .

아래 표는 사전 거래 계획(Automated trading plan)에 포함되지 않은 가장 최근의 공개 시장에서의 매매를 보여줍니다.

거래일	내부자	보고된 지분	보고된 가격	조정된 지분	조정된 가격	가격 기준	최저까지 일수	최저에서 가격	회피된 최대 손실($)	회피된 최대 손실율(%)
2020-12-02	OrbiMed Israel GP Ltd.	103,200	21.6000	103,200	21.6000	2,229,120	22	13.8100	-803,928	-36.06
2020-10-30	Logos Global Management LP	27	27.0200	27	27.0200	730
2020-10-30	Logos Global Management LP	12,942	26.6442	12,942	26.6442	344,829
2019-05-21	TURKEL CATHERINE C.	1,914	1.9114	106	34.4052	3,658
2019-05-21	FLESHER GREGORY J.	2,937	1.9114	163	34.4052	5,614

조정된 가격은 분할 조정 가격입니다. 조정된 지분은 분할 조정 지분입니다.

거래 내역

전체 거래 내역을 보려면 링크 아이콘을 클릭하세요. 10b5-1 자동 거래 계획의 일부로 보고된 거래는 10b-5 열에 X 표시가 나타납니다.

보고일	거래일	양식	내부자	티커	증권 소유권	코드	직접	행사 가격	단위 가격	단위 변동	가치 변동 (단위: 1,000)	잔여 옵션	잔여 주식
2026-01-16	2026-01-10	4	Robinson James A. Jr.	ELDN	Common Stock	M - Exercise	D			3,430			3,430
2026-01-16	2026-01-10	4	Lee June	ELDN	Common Stock	M - Exercise	D			3,430			3,430
2026-01-16	2026-01-10	4	Katkin Keith	ELDN	Common Stock	M - Exercise	D			8,575			8,575
2026-01-16	2026-01-10	4	Kirk Allan	ELDN	Common Stock	M - Exercise	D			3,430			3,430
2026-01-16	2026-01-10	4	Hillson Jan	ELDN	Common Stock	M - Exercise	D			3,430			3,430
2026-01-16	2026-01-10	4	McBride John S.	ELDN	Common Stock	M - Exercise	D			3,430			3,430
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			75,431			220,460
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			821,121			2,633,679
2024-05-13	2024-05-09	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			1,031,385			3,361,803
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			86,341			145,029
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			837,146			1,812,558
2023-05-09	2023-05-05	4	BVF PARTNERS L P/IL	ELDN	Common Stock, $0.001 par value	P - Purchase	D			1,055,445			2,330,418
2022-11-23	2022-11-23	4	Perrin Steven	ELDN	Common Stock	P - Purchase	D		2.5969	1,000	3		1,000
2022-02-02	2022-02-01	4	Gros David-Alexandre C	ELDN	Stock Option (right to buy)	A - Award	D	3.97		108,000		108,000
2022-02-02	2022-02-01	4	Smith Bryan E.	ELDN	Stock Option (right to buy)	A - Award	D	3.97		120,000		120,000
2022-02-02	2022-02-01	4	Ogier Walter C	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	Perrin Steven	ELDN	Stock Option (right to buy)	A - Award	D	3.97		155,000		155,000
2022-02-02	2022-02-01	4	McBride John S.	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	LYONS GARY A	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	Lee June	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	Hillson Jan	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	Katkin Keith	ELDN	Stock Option (right to buy)	A - Award	D	3.97		20,000		20,000
2022-02-02	2022-02-01	4	Little Paul Sean	ELDN	Stock Option (right to buy)	A - Award	D	3.97		155,000		155,000
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						975,412
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						1,274,973
2022-01-31		3	LAMPERT MARK N	ELDN	Common Stock, $0.001 par value		D						58,688
2021-12-21	2021-12-20	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		4.4800	2,000	9		9,000
2021-08-19	2021-08-17	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		6.2100	4,000	25		7,000
2021-06-14	2021-06-11	4	Little Paul Sean	ELDN	Common Stock	P - Purchase	D		8.8700	10,000	89		10,000
2021-06-10	2021-06-09	4	Gros David-Alexandre C	ELDN	Common Stock	P - Purchase	D		8.0100	3,000	24		3,000
2021-05-04	2021-05-03	4	Smith Bryan E.	ELDN	Stock Option (Right to Buy)	A - Award	D	9.91		158,500		158,500
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			-1,757		6,758
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			-9,169		39,693
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X1 Convertible Preferred Stock	C - Conversion	D			-11,776		52,145
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			-35		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			-203		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Series X Convertible Preferred	C - Conversion	D			-273		0
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			97,615			113,152
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			1,944			15,537
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			509,410			598,624
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			11,278			89,214
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			654,215			771,780
2020-12-28	2020-12-22	4	BVF PARTNERS L P/IL	NVUS	Common Stock, $0.001 par value	C - Conversion	D			15,166			117,565
2020-12-04	2020-12-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	S - Sale	I		21.6000	-103,200	-2,229		73,650
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25.5507	9,098	232		224,071
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		26.1740	15,000	393		214,973
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	S - Sale	I		27.0200	-27	-1		199,973
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25.8790	12,942	335		200,000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	S - Sale	I		26.6442	-12,942	-345		187,058
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		26.4824	15,000	397		200,000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		25.9730	4,000	104		185,000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		24.5299	31,000	760		181,000
2020-11-06	2020-10-30	4	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock	P - Purchase	I		24.0325	5,000	120		150,000
2020-11-06		3	Logos Global Management LP See Notes 1 and 2	NVUS	Common Stock		I						145,000
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						77,936
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						102,400
2020-10-05		3	LAMPERT MARK N	NVUS	Common Stock		D						13,595
2020-09-15	2020-09-11	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	500.00		1,167		1,167
2020-09-15	2020-09-11	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	500.00		1,167		1,167
2020-09-15	2020-09-11	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	500.00		2,145		2,145
2020-09-15	2020-09-11	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	500.00		5,907		5,907
2020-09-15	2020-09-11	4	Gros David-Alexandre C	NVUS	Stock Option (Right to Buy)	A - Award	D	500.00		18,278		18,278
2020-03-20	2020-03-19	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	0.26		50,000		50,000
2020-03-20	2020-03-19	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	0.26		100,000		100,000
2020-03-20	2020-03-19	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	0.26		200,000		200,000
2020-02-25	2020-01-14	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0.2000	646,204	129	0
2020-02-25	2020-01-14	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0.2000	646,204	129	0
2020-02-25	2020-01-14	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0.2000	646,204	129
2020-02-25	2020-01-14	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	S - Sale	I		0.2000	646,204	129
2019-09-30	2019-09-26	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	0.67		100,000		100,000
2019-09-30	2019-09-26	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	0.67		75,000		75,000
2019-09-30	2019-09-26	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	0.67		60,000		60,000
2019-07-15	2019-07-11	4	Chimovits Erez	NVUS	Stock Option (Right to Buy)	A - Award	D	0.88		20,000		20,000
2019-07-15	2019-07-11	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	0.88		20,000		20,000
2019-07-15	2019-07-11	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	0.88		20,000		20,000
2019-07-15	2019-07-11	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	0.88		20,000		20,000
2019-07-15	2019-07-11	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	0.88		20,000		20,000
2019-05-22	2019-05-21	4	FLESHER GREGORY J.	NVUS	Common Stock	S - Sale	D		1.9114	-2,937	-6		156,918
2019-05-22	2019-05-20	4	FLESHER GREGORY J.	NVUS	Common Stock	S - Sale	D		1.9616	-11,701	-23		159,855
2019-05-22	2019-05-21	4	Kuwahara Jon	NVUS	Common Stock	S - Sale	D		1.9114	-1,058	-2		5,974
2019-05-22	2019-05-20	4	Kuwahara Jon	NVUS	Common Stock	S - Sale	D		1.9616	-4,218	-8		7,032
2019-05-22	2019-05-21	4	TURKEL CATHERINE C.	NVUS	Common Stock	S - Sale	D		1.9114	-1,914	-4		88,662
2019-05-22	2019-05-20	4	TURKEL CATHERINE C.	NVUS	Common Stock	S - Sale	D		1.9616	-7,623	-15		90,576
2019-05-06	2019-05-02	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646,204		646,204
2019-05-06	2019-05-02	4	Chimovits Erez See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646,204		646,204
2019-05-06	2019-05-02	4	Chimovits Erez	NVUS	Common Stock	P - Purchase	I		3.1000	646,204	2,003		3,183,314
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646,204		646,204
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Warrants to Purchase Common Stock	P - Purchase	I			646,204		646,204
2019-05-06	2019-05-02	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	P - Purchase	I		3.1000	646,204	2,003		3,183,314
2019-05-02	2019-04-30	4	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, par value $0.01 per share	S - Sale	I		2.7000	-200	-1		1,065,867
2019-03-18	2019-03-14	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	3.72		25,000		25,000
2019-03-18	2019-03-14	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	3.72		90,000		90,000
2019-03-18	2019-03-14	4	FLESHER GREGORY J.	NVUS	Common Stock	A - Award	D			25,000			171,556
2019-03-18	2019-03-14	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	3.72		50,000		50,000
2019-03-18	2019-03-14	4	TURKEL CATHERINE C.	NVUS	Common Stock	A - Award	D			20,000			98,199
2018-09-13	2018-09-12	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		5.0190	16,632	83		78,199
2018-09-13	2018-09-11	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		4.5560	17,048	78		61,567
2018-09-07	2018-09-05	4	TURKEL CATHERINE C. By Spouse's IRA	NVUS	Common Stock	P - Purchase	I		3.9660	805	3		805
2018-06-14	2018-06-13	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	6.18		9,100		9,100
2018-06-14	2018-06-13	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	6.18		9,100		9,100
2018-06-14	2018-06-13	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	6.18		9,100		9,100
2018-06-14	2018-06-13	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	6.18		9,100		9,100
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2,132,134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2,132,134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2,132,134
2018-03-20		3	LIFESCI INDEX PARTNERS LLC	NVUS	Common Stock, $.001 par value		I						2,132,134
2018-03-15	2018-03-13	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	4.83		24,000		24,000
2018-03-15	2018-03-13	4	TURKEL CATHERINE C.	NVUS	Common Stock	A - Award	D			20,000			44,519
2018-03-15	2018-03-13	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	4.83		56,500		56,500
2018-03-15	2018-03-13	4	FLESHER GREGORY J.	NVUS	Common Stock	A - Award	D			30,700			146,556
2018-03-15	2018-03-13	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	4.83		12,000		12,000
2018-03-15	2018-03-13	4	Kuwahara Jon	NVUS	Common Stock	A - Award	D			11,250			11,250
2017-11-06	2017-11-06	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	4.21		50,000		50,000
2017-07-10	2017-07-10	4	Kuwahara Jon	NVUS	Stock Option (Right to Buy)	A - Award	D	5.61		35,000		35,000
2017-07-05	2017-06-30	4	Katkin Keith	NVUS	Stock Option (Right to Buy)	A - Award	D	5.85		36,000		36,000
2017-07-05	2017-06-30	4	Morrison Jodie Pope	NVUS	Stock Option (Right to Buy)	A - Award	D	5.85		18,000		18,000
2017-07-05	2017-06-30	4	Cohen Cheryl	NVUS	Stock Option (Right to Buy)	A - Award	D	5.85		18,000		18,000
2017-07-05	2017-06-30	4	McBride John S.	NVUS	Stock Option (Right to Buy)	A - Award	D	5.85		18,000		18,000
2017-07-05	2017-06-30	4	LYONS GARY A	NVUS	Stock Option (Right to Buy)	A - Award	D	5.85		18,000		18,000
2017-05-26	2017-05-24	4	OCAMPO CHRISTINE	NVUS	Stock Option (Right to Buy)	A - Award	D	5.50		52,500		52,500
2017-05-26	2017-05-24	4	TURKEL CATHERINE C.	NVUS	Stock Option (Right to Buy)	A - Award	D	5.50		52,500		52,500
2017-05-26	2017-05-24	4	FLESHER GREGORY J.	NVUS	Stock Option (Right to Buy)	A - Award	D	5.50		250,000		250,000
2017-05-11		3	LYONS GARY A	NVUS	No Securities Owned		D						0
2017-05-11		3	FLESHER GREGORY J.	NVUS	Common Stock		D						113,794
2017-05-11		3	FLESHER GREGORY J.	NVUS	Common Stock		D						113,794
2017-05-11		3	TURKEL CATHERINE C.	NVUS	Common Stock		D						26,816
2017-05-11		3	TURKEL CATHERINE C.	NVUS	Common Stock		D						26,816
2017-05-11		3	Katkin Keith	NVUS	Common Stock		D						24,238
2017-05-11		3	Katkin Keith	NVUS	Common Stock		D						24,238
2017-05-11		3	OCAMPO CHRISTINE	NVUS	Common Stock		D						23,160
2017-05-11		3	OCAMPO CHRISTINE	NVUS	Common Stock		D						23,160
2017-05-11		3	Chimovits Erez By OrbiMed Israel GP Ltd.	NVUS	Common Stock		I						5,074,220
2017-05-11		3	Chimovits Erez By OrbiMed Israel GP Ltd.	NVUS	Common Stock		I						5,074,220
2017-05-11	2017-05-10	4	FLESHER GREGORY J.	NVUS	Common Stock	P - Purchase	D		9.9900	58,959	589		115,856
2017-05-11	2017-05-10	4	OCAMPO CHRISTINE	NVUS	Common Stock	P - Purchase	D		9.9900	10,010	100		21,590
2017-05-11	2017-05-10	4	TURKEL CATHERINE C.	NVUS	Common Stock	P - Purchase	D		9.9900	11,111	111		24,519
2017-05-11	2017-05-09	4	OrbiMed Israel GP Ltd. See Footnotes	NVUS	Common Stock	A - Award	I			2,537,110			2,537,110
2016-06-16	2016-06-15	4	BARBERICH TIMOTHY J	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-06-16	2016-06-15	4	Harrison Seth Loring	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-06-16	2016-06-16	4	Cohen Cheryl	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-06-16	2016-06-15	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-06-16	2016-06-15	4	Yanchik Joseph A., III	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-06-16	2016-06-15	4	Kessler David A.	TKAI	Stock Option (right to buy)	A - Award	D	6.29		12,000		12,000
2016-03-15	2016-03-15	4	Buckley Stephen Jr.	TKAI	Common Stock	P - Purchase	D		5.7400	8,000	46		11,000
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.37		-20,000		37,878
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0.63		-8,015		0
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.3700	20,000	27		57,566
2016-01-08	2016-01-08	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0.6300	8,015	5		37,566
2015-12-17	2015-12-15	4	Ferrante Karen Jean	TKAI	Stock Option (right to buy)	A - Award	D	9.65		62,000		62,000
2015-12-17	2015-12-15	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	9.65		189,000		189,000
2015-12-17	2015-12-15	4	Kalowski Lee	TKAI	Stock Option (right to buy)	A - Award	D	9.65		62,000		62,000
2015-12-17	2015-12-15	4	McBride John S.	TKAI	Stock Option (right to buy)	A - Award	D	9.65		62,000		62,000
2015-12-17	2015-12-15	4	Quirk Gerald E	TKAI	Stock Option (right to buy)	A - Award	D	9.65		62,000		62,000
2015-11-12	2015-11-11	4	Buckley Stephen Jr.	TKAI	Common Stock	P - Purchase	D		11.2500	3,000	34		3,000
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4.19		-13,500		186,678
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14.0100	-13,500	-189		0
2015-09-22	2015-09-21	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4.1900	13,500	57		13,500
2015-09-08	2015-09-08	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		13.1300	-4,668	-61		40,953
2015-09-04	2015-09-02	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		12.9600	-2,158	-28		45,621
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.37		-3,000		57,878
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0.63		-7,000		8,015
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.58		-564		312,736
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.3700	3,000	4		29,551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0.6300	7,000	4		26,551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13.7000	-564	-8		19,551
2015-07-30	2015-07-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.5800	564	1		20,115
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.58		-12,000		313,300
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13.7000	-12,000	-164		19,551
2015-07-30	2015-07-28	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.5800	12,000	19		31,551
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	0.63		-7,426		15,015
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	2.31		-2,574		0
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		0.6300	7,426	5		19,551
2015-07-24	2015-07-22	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		2.3100	2,574	6		12,125
2015-07-17	2015-07-15	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2580	-3,566	-51		4,493,458
2015-07-15	2015-07-14	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.4100	-27,861	-401		4,497,024
2015-07-15	2015-07-13	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2020	-20,611	-293		4,524,885
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.58		-8,000		325,300
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13.7000	-8,000	-110		9,551
2015-06-30	2015-06-29	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.5800	8,000	13		17,551
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	M - Exercise	D	1.58		-8,000		333,300
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Common Stock	S - Sale	D		13.8300	-8,000	-111		9,551
2015-06-30	2015-06-26	4	Morrison Jodie Pope	TKAI	Common Stock	M - Exercise	D		1.5800	8,000	13		17,551
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4.19		-300		200,178
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14.2000	-300	-4		0
2015-06-24	2015-06-24	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4.1900	300	1		300
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4.19		-6,700		200,478
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14.0000	-6,700	-94		0
2015-06-24	2015-06-23	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4.1900	6,700	28		6,700
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Stock Option (right to buy)	M - Exercise	D	4.19		-2,000		207,178
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Common Stock	S - Sale	D		14.0200	-2,000	-28		0
2015-06-24	2015-06-22	4	McBride John S.	TKAI	Common Stock	M - Exercise	D		4.1900	2,000	8		2,000
2015-06-19	2015-06-17	4	BARBERICH TIMOTHY J	TKAI	Stock Option (right to buy)	A - Award	D	14.04		12,000		12,000
2015-06-19	2015-06-17	4	Harrison Seth Loring	TKAI	Stock Option (right to buy)	A - Award	D	14.04		12,000		12,000
2015-06-19	2015-06-17	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	14.04		12,000		12,000
2015-06-19	2015-06-17	4	Yanchik Joseph A., III	TKAI	Stock Option (right to buy)	A - Award	D	14.04		12,000		12,000
2015-06-19	2015-06-17	4	Kessler David A.	TKAI	Stock Option (right to buy)	A - Award	D	14.04		12,000		12,000
2015-06-18	2015-06-16	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2700	-1,120	-16		4,545,496
2015-06-16	2015-06-12	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2000	-5,919	-84		4,561,393
2015-06-16	2014-06-15	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2000	-14,777	-210		4,546,616
2015-06-12	2015-06-11	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.2000	-27,875	-396		4,567,312
2015-05-28	2015-05-26	4	Quirk Gerald E	TKAI	Stock Option (right to buy)	A - Award	D	10.81		214,605		214,605
2015-04-20	2015-04-16	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		13.0000	-4,567	-59		47,779
2015-04-13		3	Cohen Cheryl	TKAI	No securities are beneficially owned		D						0
2015-04-13	2015-04-09	4	Cohen Cheryl	TKAI	Stock Option (right to buy)	A - Award	D	11.08		25,000		25,000
2015-04-06	2015-04-02	4	Kalowski Lee	TKAI	Common Stock	S - Sale	D		11.4500	-2,258	-26		52,346
2015-03-20	2015-03-19	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.5000	-46,141	-669		4,595,187
2015-03-20	2015-03-18	4	Novartis Bioventures Ltd	TKAI	Common Stock	S - Sale	D		14.5000	-3,000	-44		4,641,328
2015-01-12		3	Buckley Stephen Jr.	TKAI	No securities are beneficially owned		D						0
2015-01-12	2015-01-08	4	Buckley Stephen Jr.	TKAI	Stock Option (right to buy)	A - Award	D	14.49		25,000		25,000
2014-10-17	2014-10-15	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	13.25		134,134		134,134
2014-10-17	2014-10-15	4	McBride John S.	TKAI	Stock Option (right to buy)	A - Award	D	13.25		50,671		50,671
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series E Preferred Stock	C - Conversion	I			-8,013,003		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-3 Preferred Stock	C - Conversion	I			-3,931,085		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-2 Preferred Stock	C - Conversion	I			-457,728		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Series D-1 Preferred Stock	C - Conversion	I			-4,577,315		0
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Common Stock	P - Purchase	I		15.0000	150,000	2,250		1,771,688
2014-09-24	2014-09-22	4	Satter Muneer A See footnote.	TKAI	Common Stock	C - Conversion	I			1,621,688			1,621,688
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series E Preferred Stock	C - Conversion	I			-24,199,308		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-3 Preferred Stock	C - Conversion	I			-24,046,035		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-2 Preferred Stock	C - Conversion	I			-1,539,643		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series D-1 Preferred Stock	C - Conversion	I			-8,711,335		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series C Preferred Stock	C - Conversion	I			-14,604,833		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series B-2 Preferred Stock	C - Conversion	I			-644,786		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series B-1 Preferred Stock	C - Conversion	I			-798,067		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Series A Preferred Stock	C - Conversion	I			-4,500,000		0
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Common Stock	P - Purchase	I		15.0000	362,500	5,438		7,912,079
2014-09-24	2014-09-22	4	Harrison Seth Loring See footnote.	TKAI	Common Stock	C - Conversion	I			7,549,570			7,549,579
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Series E Preferred Stock	C - Conversion	D			-24,199,308		0
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Series D-3 Preferred Stock	C - Conversion	D			-10,675,613		0
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Common Stock	P - Purchase	D		15.0000	237,500	3,562		3,568,438
2014-09-24	2014-09-22	4	Apple Tree Partners II - Annex, L.P.	TKAI	Common Stock	C - Conversion	D			3,330,938			3,330,938
2014-09-24	2014-09-22	4	Morrison Jodie Pope	TKAI	Stock Option (right to buy)	A - Award	D	1.58		165,251		165,251
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series E Preferred Stock	C - Conversion	D			-15,064,469		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-3 Preferred Stock	C - Conversion	D			-13,222,826		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-2 Preferred Stock	C - Conversion	D			-1,539,643		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Series D-1 Preferred Stock	C - Conversion	D			-15,396,431		0
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Common Stock	P - Purchase	D		15.0000	325,000	4,875		4,644,328
2014-09-24	2014-09-22	4	Novartis Bioventures Ltd	TKAI	Common Stock	C - Conversion	D			4,319,328			4,319,328
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Series E Preferred Stock	C - Conversion	D			-809,955		0
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Series D-3 Preferred Stock	C - Conversion	D			-457,731		0
2014-09-24	2014-09-22	4	BARBERICH TIMOTHY J	TKAI	Common Stock	C - Conversion	D			121,077			121,077
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-3 Preferred Stock	C - Conversion	D			-13,370,422		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-2 Preferred Stock	C - Conversion	D			-1,539,643		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series D-1 Preferred Stock	C - Conversion	D			-8,711,335		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series C Preferred Stock	C - Conversion	D			-14,604,833		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series B-2 Preferred Stock	C - Conversion	D			-644,786		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series B-1 Preferred Stock	C - Conversion	D			-798,067		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Series A Preferred Stock	C - Conversion	D			-4,500,000		0
2014-09-24	2014-09-22	4	APPLE TREE PARTNERS II LP	TKAI	Common Stock	C - Conversion	D			4,218,632			4,218,641
2014-09-24		3	Apple Tree Partners IV, L.P.	TKAI	Common Stock		D						250,000
2014-09-24		3	Apple Tree Partners IV, L.P.	TKAI	Common Stock		D						250,000
2014-09-18	2014-09-17	4	Kalowski Lee	TKAI	Stock Option (right to buy)	A - Award	D	15.00		218,417		218,417
2014-09-18	2014-09-17	4	Kalowski Lee	TKAI	Common Stock	A - Award	D			54,604			54,604
2014-09-16		3	Morrison Jodie Pope	TKAI	Common Stock		D						19,102
2014-09-16		3	Morrison Jodie Pope	TKAI	Common Stock		D						19,102
2014-09-16		3	APPLE TREE PARTNERS II LP	TKAI	Common Stock		D						18
2014-09-16		3	APPLE TREE PARTNERS II LP	TKAI	Common Stock		D						18
2014-09-16		3	Yanchik Joseph A., III	TKAI	Common Stock		D						51,092
2014-09-16		3	Yanchik Joseph A., III	TKAI	Common Stock		D						51,092
2014-09-16		3	Williams Martin D	TKAI	Common Stock		D						337,700
2014-09-16		3	Williams Martin D	TKAI	Common Stock		D						337,700
2014-09-16		3	Harrison Seth Loring See footnote.	TKAI	Common Stock		I						212,712
2014-09-16		3	Harrison Seth Loring	TKAI	Common Stock		D						425,397
2014-09-16		3	Harrison Seth Loring See footnote.	TKAI	Common Stock		I						212,712
2014-09-16		3	Harrison Seth Loring	TKAI	Common Stock		D						425,397

공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매입

공개 시장에서 또는 사적으로 비파생증권 또는 파생증권 매각

자사로부터 유가증권(옵션 등)을 보조, 지급 또는 기타 취득

파생상품 전환

자사에게 유가증권을 매각 또는 양도

기업으로부터 인도 받은 유가증권의 일부를 사용한 행사 가격 또는 조세 채무의 지급

내부자에 의한 또는 내부자에게 증권 증여

지분스왑 및 유사 위험 회피거래

자사로부터 인도 받은 파생증권(옵션 등)의 행사 또는 전환

보고서 양식 4에 자진 신고된 거래

기타 (거래 내용을 설명하는 각주와 동반)

ELDN / Eledon Pharmaceuticals, Inc. - Insider Trading and Ownership Report - SEC Form 3, 4, 5